ArticleAging2013
M(o)TOR of aging: MTOR as a universal molecular hypothalamus.
Article in Aging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Article
- The hyperfunction theory: An emerging paradigm for the biology of aging.Ageing research reviews · 2022Review
- Systems biology analysis of lung fibrosis-related genes in the bleomycin mouse model.Scientific reports · 2021Article
- The hyperfunction theory of aging: three common misconceptions.Oncoscience · 2021Article
- Article
- Crosstalk between insulin-like growth factor-1 and angiotensin-II in dopaminergic neurons and glial cells: role in neuroinflammation and aging.Oncotarget · 2016Article
- Article
- Reprogramming of energy metabolism as a driver of aging.Oncotarget · 2016Review
- Rejuvenating immunity: "anti-aging drug today" eight years later.Oncotarget · 2015Article
- Article
- Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin.Cell cycle (Georgetown, Tex.) · 2015Article
- Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.Oncotarget · 2014Article
- Gerosuppression in confluent cells.Aging · 2014Article
- Article
- Hypothalamic-mediated control of glucose balance in the presence and absence of insulin.Aging · 2014Review
- Article
- Comparison of rapamycin schedules in mice on high-fat diet.Cell cycle (Georgetown, Tex.) · 2014Article
- Aging is not programmed: genetic pseudo-program is a shadow of developmental growth.Cell cycle (Georgetown, Tex.) · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recent ground-breaking publication described hypothalamus-driven programmatic aging. As a Russian proverb goes "everything new is well-forgotten old". In 1958, Dilman proposed that aging and its related diseases are programmed by the hypothalamus. This theory, supported by beautiful experiments, remained unnoticed just to be re-discovered recently. Yet, it does not explain all manifestations of aging. And would organism age without hypothalamus? Do sensing pathways such as MTOR (mechanistic Target of Rapamycin) and IKK-beta play a role of a "molecular hypothalamus" in every cell? Are hypothalamus-driven alterations simply a part of quasi-programmed aging manifested by hyperfunction and secondary signal-resistance? Here are some answers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.